International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.

Despite attempts to improve the definitions of ambiguous lineage leukemia (ALAL) during the last 2 decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study (International Berlin-Frankfurt-Münster Study of Leukemias of Ambiguous Lineage [iBFM-AMBI2012]) of 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (EFS) of patients with acute lymphoblastic leukemia (ALL)-type primary therapy (80% ± 4%) was superior to that of children who received acute myeloid leukemia (AML)-type or combined-type treatment (36% ± 7.2% and 50% ± 12%, respectively). When ALL- or AML-specific gene fusions were excluded, 5-year EFS of CD19+ leukemia was 83% ± 5.3% on ALL-type primary treatment compared with 0% ± 0% and 28% ± 14% on AML-type and combined-type primary treatment, respectively. Superiority of ALL-type treatment was documented in single-population mixed phenotype ALAL (using World Health Organization and/or European Group for Immunophenotyping of Leukemia definitions) and bilineal ALAL. Treatment with ALL-type protocols is recommended for the majority of pediatric patients with ALAL, including cases with CD19+ ALAL. AML-type treatment is preferred in a minority of ALAL cases with CD19- and no other lymphoid features. No overall benefit of transplantation was documented, and it could be introduced in some patients with a poor response to treatment. As no clear indicator was found for a change in treatment type, this is to be considered only in cases with ≥5% blasts after remission induction. The results provide a basis for a prospective trial.

[1]  T. Leong,et al.  Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival. , 2018, Blood.

[2]  Barbara Buldini,et al.  AIEOP‐BFM Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia , 2018, Cytometry. Part B, Clinical cytometry.

[3]  J. Stuchly,et al.  ETV6/RUNX1‐like acute lymphoblastic leukemia: A novel B‐cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype , 2017, Genes, chromosomes & cancer.

[4]  M. Loh,et al.  Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. , 2017, Blood.

[5]  K. Okamura,et al.  ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype , 2017, Haematologica.

[6]  A. Pomerantz,et al.  Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used , 2016, Blood research.

[7]  E. Mejstrikova,et al.  Distinct bilineal leukemia immunophenotypes are not genetically determined. , 2016, Blood.

[8]  D. Wheeler,et al.  Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. , 2016, Experimental hematology.

[9]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[10]  J. Harbott,et al.  Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. , 2016, Blood.

[11]  J. Choi,et al.  t(12;17)(p13;q12)/TAF15-ZNF384 Rearrangement in Acute Lymphoblastic Leukemia , 2016, Annals of laboratory medicine.

[12]  G. Leverger,et al.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Saxena,et al.  Can threshold for MPO by flow cytometry be reduced in classifying acute leukaemia? A comparison of flow cytometric and cytochemical myeloperoxidase using different flow cytometric cut-offs , 2015, Hematology.

[14]  E. Mejstrikova,et al.  Reprogramming of B cell acute lymphoblastic leukemia cells: Do we need to shoot a moving target? , 2015, Proceedings of the National Academy of Sciences.

[15]  N. Heerema,et al.  Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 , 2014, Leukemia.

[16]  T. Kalina,et al.  CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage , 2014, Leukemia.

[17]  F. Lacombe,et al.  Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia , 2013, British journal of haematology.

[18]  G. Ossenkoppele,et al.  A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin , 2013, Cytometry. Part B, Clinical cytometry.

[19]  E. Thiel,et al.  Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization , 2013, Annals of Hematology.

[20]  Xiuli Wu,et al.  Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens , 2013, Annals of Hematology.

[21]  A. Bernasconi,et al.  Lineage switch in childhood acute leukemia: An unusual event with poor outcome , 2012, American journal of hematology.

[22]  J. V. van Dongen,et al.  Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. , 2011, Blood.

[23]  A. Órfão,et al.  Mixed phenotype acute leukemia (MPAL): clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification Authors: , 2011 .

[24]  N. Friedman,et al.  Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis , 2011, Cell.

[25]  T. Kalina,et al.  Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria , 2010, Haematologica.

[26]  J. V. van Dongen,et al.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.

[27]  M. Schrappe,et al.  Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations , 2010, British journal of haematology.

[28]  O. Haas,et al.  Cytochemically Myeloperoxidase Positive Childhood Acute Leukemia With Lymphoblastic Morphology Treated as Lymphoblastic Leukemia , 2010, Journal of pediatric hematology/oncology.

[29]  J. Downing,et al.  Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. , 2009, Blood.

[30]  O. Hrusak,et al.  Antigen expression patterns reflecting genotype of acute leukemias , 2002, Leukemia.

[31]  W. Hop,et al.  Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. , 2002, Blood.

[32]  M. Borowitz,et al.  Acute leukaemias of ambiguous lineage. . , 2001 .

[33]  A. Órfão,et al.  The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated Leukemias , 1998 .

[34]  E. Paietta.  Proposals for the immunological classification of acute leukemias. , 1995, Leukemia.

[35]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[36]  S. Raimondi,et al.  Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. , 1991, Blood.